Context Therapeutics Inc. Announces Closing of $31.25 Million Private Placement

NEXT STORY
Yamana Gold Receives Permit at Jacobina, Initiating Ramp Up of Phase 2 Expansion, Expects Fourth Quarter Company Wide Production to Exceed 270,000 GEO With Costs Tracking to Be the Lowest of the Year
PREV STORY
Monthly information on share capital and company voting rights
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

Abeona Therapeutics Receives Rare Pediatric Disease Designation for EB-101 Gene Therapy Product for Patients with Epidermolysis Bullosa

NEW YORK and CLEVELAND, May 30, 2017 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq:ABEO), ...

author_avatar
NASDAQ Market News

Emergent BioSolutions Announces Commencement of When Issued Trading of Aptevo Common Stock

GAITHERSBURG, Md., July 20, 2016 (GLOBE NEWSWIRE) -- In connection with the spin-off of ...

author_avatar
NASDAQ Market News

CureVac Appoints Dimitris Voliotis, M.D., Dr. med., as Chief Development Officer

Drug development veteran to lead CureVac’s global product development efforts as the company looks ...

author_avatar
NASDAQ Market News